Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: John Carragher who wrote (8487)	9/5/2003 11:42:26 PM
From: Shawn Donahue	Read Replies (1) \| Respond to of 9523

John, I don't know how many small companies that Pfizer has R&D agreements with, but they are certainly seem to be out there trying to get a competitive edge on bringing new drugs to market...below is one company that they 1st signed a one year research agreement with, and then a 15 year license agreement, which I know from owning the stock and reading the SEC filings, as there was no press release on the license agreement, that I am aware of. Anyway, I read quite a few articles in Forbes about Pfizer, to help get insight into what areas they are spending their R&D on...and I agree with your comment about them spending alot on R&D, which I would think they have to, but hopefully in the right areas. Shawn MultiCell Signs Collaborative Research Agreement with Pfizer San Diego, CA – November 15 /PR Newswire/ – Exten Industries, Inc. (Exten): (OTC BB: EXTI.OB) announced today that its wholly owned subsidiary, MultiCell Technologies Inc. (MultiCell), a cellular engineering and research organization in Warwick, RI, has just signed a Collaborative Research Agreement with Pfizer Inc. Specific terms were not disclosed. MultiCell is dedicated to the development and commercialization of hepatic (liver) cells, cell lines, and biologics for use in diagnostic and therapeutic applications. MultiCell’s cellular products enable cell transplantation, vaccine development and therapeutic protein production. The company will develop cell based toxicological and drug screening tests for use by the pharmaceutical industry and others. The agreement with Pfizer involves validation of MultiCell’s immortalized liver cells to predict, among other things, the toxicological and therapeutic properties of drug candidates. “We believe that our cells may profoundly impact the drug discovery paradigm,” stated Greg Szabo, acting CEO of MultiCell. We envision that the cell lines provided by MultiCell will facilitate early identification of potentially harmful side effects such as drug-drug interactions. As a result, our technology may ultimately lead to more efficient and cost effective production of new drugs. We believe that Pfizer is the first of many pharmaceutical companies that can benefit from our technology.” Ron Faris, President and CSO of MultiCell commented, “The Company is very enthusiastic to initiate its collaborative studies with Pfizer. We feel that our technology will provide the pharmaceutical industry with a unique and valuable tool for drug discovery.” exten.com